16-Jan-2015, Spontaneous, Patient/Consumer Serious report . ( Sanofi Aventis: 1-669620137).
A Consumer/other non health professional reported the case of a male patient (age unknown) who received 
COPAXONE (GLATIRAMER ACETATE, Product is a Teva product). 
The patient took COPAXONE for MULTIPLE SCLEROSIS (GLATIRAMER ACETATE, Injection, unknown form 
strength).
While on the suspect medication(s), the patient experienced POSITIVE FOR JC VIRUS(Serious ); ISSUES WITH 
SCARRING AT INJECTION SITES(Not Serious ) .
Patient reported that he had issues with scarring at injection sites and he is positive for JC virus. No other 
information available. 
At the time of the report the outcome of the AEs were:   POSITIVE FOR JC VIRUS : Unknown,   ISSUES WITH 
SCARRING AT INJECTION SITES : Unknown.
Action taken with suspect drugs: COPAXONE - Unknown.
Print Time: 26-MAY-2016 01:56 PM If a field is blank, there is no data for that field Page 428 of 675
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The patient had medical history of MULTIPLE SCLEROSIS(Continuing).
The patient's concomitant medication were unspecified.
The patient's past medication were unspecified. 
Lab tests were not reported.
This case was considered serious based on the following criteria: (Other Serious (Important Medical Events))
Teva Comment:  GLATIRAMER ACETATE   JC virus is most probably associated with underlying disease of 
multiple sclerosis and its complications. Causality: Not related to Copaxone.
Because this is a spontaneous case, regulatory distribution will be handled as though it is a related case.